Latest stories on TCRX
TScan Therapeutics Launches Executive Retention Incentive Program
TipRanks55 · neutralgeneral
TScan Therapeutics, Inc. (TCRX) files 8-K
SEC 8-K50 · neutralgeneral
TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
The Fly48 · neutralanalyst
Needham downgrades TScan Therapeutics as company reprioritizes
The Fly34 · bearishanalyst
TScan Therapeutics downgraded to Hold from Buy at Needham
The Fly48 · neutralanalyst
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift
Investing.com Analyst Ratings46 · neutralanalyst
TScan Therapeutics downgraded to Neutral from Outperform at Wedbush
The Fly46 · neutralanalyst
Why is TScan Therapeutics stock collapsing today?
Investing.com Markets32 · bearishgeneral
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
Yahoo Top28 · bearishgeneral
TScan Therapeutics to strategically reorganize, reduce workforce by 75%
The Fly28 · bearishgeneral
TScan Therapeutics, Inc. (TCRX) files 8-K
SEC 8-K50 · neutralgeneral
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
StockTitan56 · neutralgeneral
TScan Therapeutics, Inc. (TCRX) files 8-K
SEC 8-K50 · neutralgeneral
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
TScan Therapeutics, Inc. (TCRX) files 8-K
SEC 8-K50 · neutralgeneral
TScan Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.05M misses by $0.83M
Seeking Alpha34 · bearishearnings
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire59 · neutralearnings
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Business Insider56 · neutralgeneral
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
Business Insider63 · neutralproduct/pr
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
TipRanks67 · bullishproduct/pr
TScan Therapeutics, Inc. (TCRX) files 8-K
SEC 8-K50 · neutralgeneral